While adding a 53rd biosimilar under its belt, the US Food and Drug Administration also marked a first. The agency approved Amgen’s Bkemv (eculizumab-aeeb) as the first biosimilar rival to Alexion’s Soliris (eculizumab), along with a designation of interchangeability.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?